Napro Biotherapeutics (NASDAQ:NPRO)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Napro Biotherapeutics Charts. Click Here for more Napro Biotherapeutics Charts.](/p.php?pid=staticchart&s=N%5ENPRO&p=8&t=15)
NaPro BioTherapeutics to Present at the Wells Fargo Securities Health Care
Conference
BOULDER, Colo., March 22 /PRNewswire-FirstCall/ -- NaPro BioTherapeutics, Inc.
today announced that Leonard Shaykin, Chairman and Chief Executive Officer of
NaPro, will present an overview of the Company's progress and strategy at the
Wells Fargo Securities Health Care "Fireside Chats" Conference on Wednesday,
March 24, 2004 at 3:15 PM Eastern Time at the St. Regis Hotel in New York City.
Wells Fargo will provide a live audio webcast of the presentation, which can be
accessed through NaPro's website at http://www.naprobio.com/. A replay of the
webcast will be available for 90 days.
About NaPro BioTherapeutics
NaPro BioTherapeutics, Inc., is a life science company focused on the
development of therapies for the treatment of cancer and hereditary disease.
Forward Looking Statements
The statements in the webcast presentation that are not historical facts are
forward-looking statements that represent management's beliefs and assumptions
as of the date of the webcast presentation, based on currently available
information. Forward-looking statements can be identified by the use of words
such as "believes," "intends," "estimates," "may," "will," "should,"
"anticipates," "expected" or comparable terminology or by discussions of
strategy. Although the Company believes that the expectations reflected in such
forward-looking statements are reasonable, it cannot assure that these
expectations will prove to be correct. Such statements involve risks and
uncertainties including those factors identified under the captions "Risk
Factors," "Special Note Regarding Forward Looking Statements" or "Cautionary
Note Regarding Forward Looking Statements" in the Company's documents filed from
time to time with the SEC, including the Company's Current Report on Form 8-K/A,
dated February 11, 2004, and its Annual Report on Form 10-K for the year ending
December 31, 2003 filed with the SEC on March 11, 2004. Should one or more of
these risks materialize (or the consequences of such a development worsen), or
should the underlying assumptions prove incorrect, actual results could differ
materially from those forecasted or expected. The Company disclaims any
intention or obligation to update publicly or revise such statements whether as
a result of new information, future events or otherwise.
For further information, please contact L. Robert Cohen, Vice President,
Investor Relations of NaPro BioTherapeutics, Inc., +1-212-218-8715.
DATASOURCE: NaPro BioTherapeutics, Inc.
CONTACT: L. Robert Cohen, Vice President, Investor Relations of NaPro
BioTherapeutics, Inc., +1-212-218-8715; or Investors, Lilian Stern of Stern
Investor Relations, Inc., +1-212-362-1200, or Media, Peter Steinerman,
+1-516-374-3031, both for NaPro BioTherapeutics, Inc.
Web site: http://www.naprobio.com/